> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Meitheal Recalls Cisatracurium Besylate Injection
- URL: https://www.fdaweb.com/meitheal-recalls-cisatracurium-besylate-injection/
- Published: 2021-01-28T12:00:00.000Z
- Updated: 2026-09-14T16:44:33.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148545

FDA says Meitheal Pharmaceuticals is recalling one lot of cisatracurium besylate 10mg per 5 mL injection due to mislabeling. A company [statement](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/meitheal-pharmaceuticals-inc-issues-voluntary-nationwide-recall-cisatracurium-besylate-injection-usp?utm%5Fmedium=email&utm%5Fsource=govdelivery#recall-announcement) says the recall decision was made after a product complaint found that some cartons in the lot were mislabeled as phenylephrine HCl injection 100mg per mL. The company says it has not received reports of any adverse events or identifiable safety concerns attributed to the lot.

Cisatracurium besylate injection is a nondepolarizing neuromuscular blocker, Meitheal says. The affected lot has a 10/2021 expiration date and was shipped starting 8/19/20 to wholesalers nationwide in the U.S.